medigraphic.com

2015, Number S2

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2015; 53 (S2)

Epidemiological overview of uterine cervical cancer

Hernández-Hernández DM, Apresa-García T, Patlán-Pérez RM

Language: Spanish
References: 33
Page: 154-161
PDF size: 296.04 Kb.


ABSTRACT

The World Health Organization (WHO) reported more than 6 million cases of cancer worldwide in women during 2008; 57.2 % of those cases occurred in less developed countries. Cervical cancer (CC) ranks third in the world in all cancers affecting women, with an estimated of 530 000 new cases. CC has multiple causes and it arises by the association of various risk factors. The main factor is related to the human papillomavirus infection (HPV), which acts as a necessary but not sufficient cause. Also, the interaction with other cofactors has an impact on the development and severity of this neoplasm. Survival is related to the timeliness of care and, therefore, to more access to health services. CC is a neoplasm considered a preventable cancer; thus, it is possible to save more than 150 000 lives by 2030 if control measures are applied with opportunity. The aim of this work is to review the CC in different geographical areas and to make an analysis of risk factors related to this neoplasm.


REFERENCES

  1. International Agency for Research on Cancer. World Health Organization. [Internet]. GLOBOCAN 2008. Estimated cancer incidence, mortality, prevalence and disability-adjusted life years worldwide in 2008. Disponible en: http://globocan.iarc.fr/

  2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v2.0, Cancer incidence and mortality world¬wide: IARC Cancer Base No. 10 [Internet]. Lyon, France: Inter-national Agency for Research on Cancer; 2010. Disponible en: http:// globocan.iarc.fr

  3. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127(12):2893-917.

  4. Parkin DM, Ferlay J, Curado MP, Bray F, Edwards B, Shin HR, Forman D. Fifty years of cancer incidence: C15 I-IX. Int J Cancer 2010; 127(12):2918-27. doi: 10.1002/ijc.25517.

  5. Brookfield KF, Cheng MC, Lucci J, Fleming LE, Koniaris LG. Disparities in survival among women with invasive cervical cancer. A problem of access to care. Cancer 2009;115(1):166-78.doi: 10.1002/cncr.24007.

  6. Knaul FM, Bhadelia A, Gralow J, Arreola-Ornelas H, Langer A, Frenk J. Meeting the emerging challenge of breast and cervical cancer in low-and middleincome countries. Int J Gynaecol Obstet 2012;119 (Suppl 1): S85-8. Epub 2012 Aug 9. PubMed: 2012;11985-8..11985-8.

  7. Siegel R, Nishadham D, Jemal A. Cancer satistics for Hispanics/Latinos, 2012. Ca Cancer J Clin 2012;62(5):283-298. doi: 10.3322/caac.21153.

  8. Bosetti C, Rodríguez T, Chatenoud L, Bertuccio P, Levi G, Negri E, La Vecchia C. Trends in cancer mortality in Mexico, 1981-2007. Eur J Ca Preven 2011;20(5):355- 363. doi: 10.1097/CEJ.0b013e32834653c9.

  9. Instituto Mexicano del Seguro Social, Dirección de Prestaciones Médicas, Unidad de Salud Pública, Coordinación de Vigilancia Epidemiológica y Apoyo a Contingencias, Boletín Epidemiológico, Morbilidad y Mortalidad por enfermedades no transmisibles, 2011. p. 84

  10. National Cancer Institute Workshop. The 1988 Bethesda System for reporting cervical/vaginal cytological diagnoses. JAMA 1989; 262(7):931-4.

  11. Solomon F, Davey D, Kurman R. The Bethesda system 2001: terminology for reporting the results of cervical cytology. JAMA 2002;287(16):2115-9.

  12. Melnikow J, Nuovo J, Willan AR, Chan BK, Howell LP. Natural history of cervical squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol 1998; 92(4 Pt 2):727-35.

  13. Wheeler CM. Natural history of human papillomavirus infections, cytologic and histologic, abnormalities, and cancer. Obstet Gynecol Clin N Am 2008;35(4):519-536.

  14. Moscicki AB, Schiffman M, Kjaer S, Villa LL. Chapter 5: Updating the natural history of HPV and anogenital cancer. Vaccine 2006;24 (Suppl 3):S3:42-51.

  15. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et.al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189(1):12-9.

  16. De Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, et.al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 2012 Jun;13(6):607-15.

  17. Bosch FX, de Sanjosé S. The epidemiology of human papillomavirus infection and cervical cancer. Dis Markers 2007; 23(4):213-27. Texto libre: http://www. ncbi.nlm.nih.gov/pmc/articles/PMC3850867/

  18. Thulaseedharn JV, Malila N, Hakama M, Esmy PO, Cheriyan M, Swaminathan R, et.al. Socio demographic and reproductive risk factors for cervical cancer - a large prospective cohort study from rural India. Asian Pac J Cancer Prev 2012;13(6):2991-5.

  19. Paba P, Bonifacio D, Di Bonito L, Ombres D, Favalli C, Syrjänen K, Ciotti M. Co-expression of HSV2 and Chlamydia trachomatis in HPV-positive cervical cáncer and cervical intraepithelia neoplasia lesions is associated with aberrations in key intracelular pathways. Intervirology 2008;51(4):230-234. Texto libre: http://www.karger.com/Article/Abstract/156481

  20. Williams VM, Flippova M, Soto U, Duerksen-Hughes PJ. HPV-DNA integration and carcinogenesis: putative roles for inflammation and oxidative stress. Future Virol. 2011 Jan 1;6(1):45-57.

  21. Bhatla N, Puri K, Joseph E, Kriplani A, Iyer VK, Sreenivas V. Association of Chlamydia trachomatis infection with human papillomavirus (HPV) & cervical intraepithelial neoplasia - a pilot study. Indian J Med Res. 2013;137(3):533-9. Texto libre: http://www.ncbi. nlm.nih.gov/pmc/articles/PMC3705662/

  22. Singh DK, Anastos K, Hoover DR, Burk RD, Shi Q, Ngendahayo L, Mutimura E, Castle P. Human papillomavirus infection and cervical cytology in HIV-infected and HIV-uninfected Rwandan women. J Infect Dis 2009;199(12):1851-1861. Texto libre: http://www. ncbi.nlm.nih.gov/pmc/articles/PMC2814215/

  23. International Collaboration of Epidemiological Stud ies of Cervical Cancer. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16573 women with cervical cancer and 35 509 women without cervical cancer from 24 epidemiological studies. Lancet 2007;370(95099):1609-1621

  24. Bicho MC, Pereira da Silva A, Matos A, Medeiros SR, Diamantino BM. Sex steroid hormones influence the risk for cervical cáncer: modulation by haptoglobin genetic polymorphism. Cancer Genet Cytogenet 2009;191(2):85-89.

  25. Helberg D, Stendahl U. The biological role of smoking, oral contraceptive use and endogenous sexual steroid hormones in invasive squamous epithelial cervical cancer. Anticancer Res 2005;25(4):3141-3146.

  26. Cedillo-Juárez T, Vallejo M, Fragoso JM, Hernández- Hernández DM, Rodríguez-Pérez JM, Sánchez-García JM, et.al. The risk of developing cervical cancer in Mexican women is associated to CYP1A1 MspI polymorphism. Eur J Cancer 2007;43(10):1590-1595.

  27. Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, et.al. Global burden of human papillomavirus and related diseases. Vaccine. 2012 Nov 20;30 (Suppl 5):F12-23. doi: 10.1016/j. vaccine.2012.07.055.

  28. Hernández HDM, Ornelas-Bernal L, Guido-Jiménez MC, Apresa-García T, Alvarado-Cabrero I, Salcedo- Vargas et.al. Association between High-risk human papillomavirus DNA load and precursor lesions of cervical cancer in Mexican women. Ginecol Oncol 2003; 90(2):310-317.

  29. de Villiers EM. Cross-roads in the classification of papillomaviruses. Virology 2013 445(1-2) ):2-10. doi: 10.1016/j.virol.2013.04.023. Epub 2013 May 16.

  30. Peralta-Rodríguez R, Romero-Morelos P, Villegas- Ruíz V, Mendoza-Rodríguez M, Taniguchi-Ponciano K, González-Yebra B, et.al. Prevalence of human papillomavirus in the cervical epithelium of Mexican women: meta-analysis. Infect Agent Cancer. 2012;7(1):34. Taxto libre: http://www.ncbi.nlm.nih. gov/pmc/articles/PMC3586354/

  31. Lizano M, De la Cruz-Hernandez E, Carrillo-García A, Ponce de Leon-Rosales S, García-Carrancá A, Dueñas- Gonzalez A, et.al. Distribution of HPV-16 and -18 intratypic variants in normal cytology, Gynecol Oncol 2006; 102(2):230-5. Texto libre: http://www.sciencedirect. com/science/article/pii/S0090825805010656

  32. Marais DJ, Sampson CC, Urban MI, Sitas F, Williamson AL. The seroprevalence of IgG antiboides to human papillomavirus (HPV) types HPV-16, HPV- 18, and HPV-11 capsid-antigens in mothers and their children. J Med Virol 2007;79(9):1370-1374.

  33. Hemminki K, Bowang Ch. Familial risks for cervical tumors in full and half siblings: etiologic apportioning. Cancer Epidemiol Biomarkers Prev 2006;15(7):1413- 1414. Texto libre: http://cebp.aacrjournals.org/cgi/pmi dlookup?view=long&pmid=16835346




2020     |     www.medigraphic.com